Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
G
G

Gerresheimer


Balita

Adidas, Spirax Group, Stroeer

EUROPE RESEARCH ROUNDUP-Adidas, Spirax Group, Stroeer July 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adidas, Spirax Group and Stroeer, on Wednesday. HIGHLIGHTS * Adidas AG ADSGn.DE : JP Morgan raises target price to EUR 260 from EUR 250 * J D Wetherspoon JDW.L : Jefferies raises target price to 1,000p from 925p * Spirax Group SPX.L : HSBC raises to hold from reduce * Stroeer SAXG.DE : HSBC raises target price to EUR 79 fro
A
A
A
A
A
B
B
C
D
D
E
E
E
F
F
G
R
S
S
U
A
A
E
E
R
S
U

Hargreaves Lansdown, Spectris, Wizz Air

EUROPE RESEARCH ROUNDUP-Hargreaves Lansdown, Spectris, Wizz Air July 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Hargreaves Lansdown, Spectris and Wizz Air, on Friday. HIGHLIGHTS * Hargreaves Lansdown HRGV.L : JP Morgan raises target price to 684p from 671p * Spectris Plc SXS.L : Jefferies cuts target price to 4190p from 4435p * Spirax-Sarco SPX.L : Jefferies cuts target price to 9580p from 9690p * Weir Group WEIR.L : Jefferi
A
A
B
B
B
C
C
D
E
E
E
E
E
G
H
H
I
L
L
M
R
R
S
S
W
A
D

Gerresheimer Exec On Conference Call - Estimate Revenue Growth To Be Around Lower End Of Our Guidance Range For 2024

BRIEF-Gerresheimer Exec On Conference Call - Estimate Revenue Growth To Be Around Lower End Of Our Guidance Range For 2024 July 11 (Reuters) - GERRESHEIMER AG GXIG.DE : EXEC ON CONFERENCE CALL - ESTIMATE REVENUE GROWTH TO BE AROUND LOWER END OF OUR GUIDANCE RANGE FOR 2024 Further company coverage: GXIG.DE (Gdansk Newsroom)
G

Gerresheimer up as guidance confirmation reassures, analysts say

BUZZ-Gerresheimer up as guidance confirmation reassures, analysts say ** Shares in Gerresheimer GXIG.DE rise around 2% in early Frankfurt trade after the German medical packaging devices maker reported a small earnings beat and stuck to its FY guidance ** "Good enough," J.P.Morgan says on the Q2 results, pointing to adjusted EBITDA coming in 2.5% a
G

Gerresheimer's weight-loss drug deals pipeline helps profits meet forecasts

UPDATE 2-Gerresheimer's weight-loss drug deals pipeline helps profits meet forecasts Adds guidance in paragraph 4, CEO comment in paragraph 3-5, analyst comment in paragraph 6 By Isabel Demetz July 11 (Reuters) - Medical equipment group Gerresheimer GXIG.DE posted second-quarter adjusted core profit in line with expectations on Thursday, driven by the deal pipeline for its plastics and devices business, which supplies weight-loss drug makers with autoinjector pens.
G

Gerresheimer's second-quarter results in line with expectations

Gerresheimer's second-quarter results in line with expectations July 11 (Reuters) - German packaging and medical equipment maker Gerresheimer GXIG.DE reported second-quarter core profit in line with market expectations on Thursday. Negative destocking effects in its primary packaging glass division were offset by the good performance of its plastics and devices division, it said.
G

Gerresheimer confirms 2024 guidance

BRIEF-Gerresheimer confirms 2024 guidance July 11 (Reuters) - Gerresheimer AG GXIG.DE : GERRESHEIMER AG - GERRESHEIMER REMAINS ON TRACK IN 1ST HALF YEAR 2024 GERRESHEIMER AG - ORGANIC GROWTH: REVENUES +1.7%, ADJUSTED EBITDA +2.9% GERRESHEIMER AG - PLASTICS & DEVICES DIVISION WITH GOOD REVENUE GROWTH AND SIGNIFICANTLY IMPROVED MARGIN GERRESHEIMER AG
G

Europe's STOXX 600 corporate earnings week ahead

DIARY-Europe's STOXX 600 corporate earnings week ahead July 5 (Reuters) - Diary of Europe's STOXX 600 (.STOXX) corporate earnings for the week ahead EUROPE'S STOXX 600 EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 08-Jul-2024 NTS INDUa.ST Industrivarden AB Q2 2024 Industrivarden AB Earnings Release 08-Jul-2024 05:30 WIHL.ST Wihlborgs Fastigheter AB Q2 2024 Wihlborgs Fastigheter AB Earnings Release 09-Jul-2024 06:00 KINVb.ST Kinnevik AB Q2 2024 Kinnevik AB Earnings Release 10-J
E
E
G
I
K
S

Obesity drug injections maker Gerresheimer expands capacity in US

Obesity drug injections maker Gerresheimer expands capacity in US May 27 (Reuters) - German drug vial maker Gerresheimer GXIG.DE on Monday announced an expansion of its U.S. production site as it sees growing demand for weight-loss drugs, including of the GLP-1 class. The company is investing around 166 million euros ($180.24 million) in the construction of two buildings, creating 400 new jobs in Peachtree.
G

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Thyssenkrupp, Hg, Hess Corp, Millicom International Cellular May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: * * Thyssenkrupp TKAG.DE said its supervisory board approved a planned sale of 20% of the conglomerate's steel division to Czech billionaire Daniel Kretinsky in the face of continued opposition from labour representatives.
C
G
H
T
A

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Updates: May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Thursday: ** Nationwide Building Society NBS.L said it could realise as much as a 1.5 billion pound ($1.91 billion) gain on its acquisition of rival Virgin Money, announced earlier this year and expected to close in the fourth quarter.
G
H
A

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Thursday: ** Nationwide Building Society NBS.L said it could realise as much as a 1.5 billion pound ($1.91 billion) gain on its acquisition of rival Virgin Money, announced earlier this year and expected to close in the fourth quarter.
G
H
A

Gerresheimer shares shine on deal to buy Blitz LuxCo Sarl

BUZZ-Gerresheimer shares shine on deal to buy Blitz LuxCo Sarl ** Shares in Gerresheimer GXIG.DE jump 12.1% after the German medical equipment maker said it had signed a purchase agreement to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group for 800 million euros ($865.92 million) ** The transaction will be financed by a consortium of banks consisting of UniCredit, Commerzbank CBKG.DE and LBBW and is expected to close in Q4, according to the statement ** "We expect the m
C
G
U

Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln

UPDATE 1-Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln Adds details in paragraphs 2 and 3 and background in 4 and 5 May 23 (Reuters) - German packaging and medical equipment maker Gerresheimer GXIG.DE said on Thursday it signed a purchase agreement for acquiring Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group, for an enterprise value of 800 million euros ($866.32 million).
C
G
U

Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln

Germany's Gerresheimer to acquire Blitz LuxCo for $866 mln May 23 (Reuters) - German packaging and medical equipment maker Gerresheimer GXIG.DE said on Thursday it signed a purchase agreement for acquiring Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group, for an enterprise value of 800 million euros ($866.32 million). ($1 = 0.9234
G

Gerresheimer Says To Acquire Blitz Luxco Sarl, The Holding Company Of The Bormioli Pharma Group

BRIEF-Gerresheimer Says To Acquire Blitz Luxco Sarl, The Holding Company Of The Bormioli Pharma Group May 23 (Reuters) - Gerresheimer AG GXIG.DE : EQS-ADHOC: GERRESHEIMER TO ACQUIRE BLITZ LUXCO SARL, THE HOLDING COMPANY OF THE BORMIOLI PHARMA GROUP / MOULDED GLASS BUSINESS TO BE STRATEGICALLY REVIEWED PURCHASE PRICE IS BASED ON A DETERMINED ENTERPR
G

UBS starts Gerresheimer with 'buy' on 1 exposure

BUZZ-UBS starts Gerresheimer with 'buy' on GLP-1 exposure ** UBS initiates Gerresheimer GXIG.DE with "buy," as it sees the German medical packaging supplier as an attractive play on GLP-1 class of diabetes and weight-loss drugs ** The brokerage highlights Gerresheimer's exposure to all relevant players and optionality stemming from CagriSema, one o
G

Alfa Laval, OMV AG, Unilever Plc

EUROPE RESEARCH ROUNDUP- Alfa Laval, OMV AG, Unilever Plc May 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfa Laval, OMV AG and Unilever Plc, on Tuesday. HIGHLIGHTS * Alfa Laval ALFA.ST : JP Morgan raises target price to SEK 385 from SEK 325 * Babcock International BAB.L : Citigroup raises target price to 640p from 530p * OMV AG OMVV.VI : Morgan Stanley raises to equal weight from underweight * SKAN Group AG SKAN.S : Baader
A
A
A
B
C
C
D
F
G
H
I
I
I
L
M
O
O
P
S
S
S
T
A
B
B
D
J
P



Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.